Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
Revenue Compound Annual Growth Rate in the last 5 years.
Operating Income Compound Annual Growth Rate in the last 5 years.
Net Income Compound Annual Growth Rate in the last 5 years.
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
...and much more!